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ABSTRACT 
AIM:-To determine the association of risk factors in type 2 diabetic 
patients with diabetic macular ischemia. Materials and methods:-A cross 
sectional study was performed on 100 diabetic patients attending the out 
patient department of ophthalmology, govt Stanley medical 
college,Chennai, during the period November 2012 to October 2013. 
Patients who filled the inclusion criteria were included in the study. 
Detailed history about systemic medical illness and ophthalmic history 
were elicited. Ophthalmic examination included V/A,refraction, slit lamp 
examination of the anterior segment, IOP and fundus examination. 
Diabetic retinopathy graded according to the abbreviated ETDRS severity 
scale. Fundus fluorescein angiography done and diabetic macular 
ischemia graded according to the criteria followed by bresnick et al. 
Systemic examination included BP recording, lab investigations FBS, 
PPBS, HbA1c, lipid profile,urine routine,ECG done. Significance of 
associations are analysed using chi square test and all the significant 
variables in univariate analysis were included in the multivariate analysis 
to calculate adjusted odds ratio for the individual factors. Results:- The 
association of diabetic macular ischemia with nephropathy and 
uncontrolled DM were found to be statistically significant (OR 4.5, 95% 
CI 1.8-11.0, P value .001); (OR 2.9, 95% CI 1.2-7.4, P value .02) 
respectively,the association of other variables age,gender,duration of DM, 
HTN, IHD, hyperlipidaemia were p value 0.912,0.500, 0.539, 0.554, 
0.476, 0.201 respectively not found to be significant. 9/13 eyes (69.23%) 
in severe;13/22eyes (59.1%) in moderate; 1/6 eyes(16.7%) in mild 
diabetic macular ischemia showed decreased visual acuity. Conclusion:-
In our study the most significant associated factor was nephropathy 
followed by uncontrolled diabetes and the other factors like duration of 
DM, HTN, IHD, hyperlipidaemia were not as significantly associated as 
nephropathy. Also we found that visual acuity is more affected in severe 
grades of diabetic macular ischemia and preserved in milder grades of 
diabetic macular ischemia. 
Key words: diabetic macular ischemia, fundus fluorescein angiography, 
HbA1c, diabetes mellitus,hypertension, IHD, hyperlipidaemia, risk 
factors, visual acuity, odds ratio. 
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ABBREVIATIONS 
 
DM    : Diabetes Mellitus 
DMI    : Diabetic Macular Ischemia 
FAZ    : Foveal Avascular Zone 
DME   : Diabetic Macular Edema 
ETDRS  : Early Treatment Diabetic Retinopathy Study 
DR    : Diabetic Retinopathy 
HTN    : Hypertension 
IHD    : Ischemic Heart Disease 
DCCT  : Diabetes Control and Clinical Trial 
UKPDS  : United Kingdom Prospective Diabetes Study 
WESDR : Wisconsin Epidemiology Study of Diabetic  
  Retinopathy 
V/A : Visual Acuity 
Hb : Haemoglobin 
MI : Myocardial Infarction 
HDL : High Density Lipoprotein 
HLA : Human Leucocyte Antigen 
RBC : Red Blood Cell 
VEGF : Vascular endothelial Growth Factor 
IRMA : Intra Retinal Microvascular Abnormalities 
NPDR : Non Proliferative Diabetic Retinopathy 
PDR : Proliferative Diabetic Retinopathy 
NVD : Neovascularisation Disc 
NVE : Neovascularisation Elsewhere 
FFA : Fundus Fluorescein Angiography 
FA : Fluorescein Angiography 
h/o : History of 
CCD : Charge Coupled Device 
HbA1C : Glycosylated haemoglobin 
ECG : Electrocardiogram 
ADA : American Diabetes Association 
JNC : Joint National Committee 
BP : Blood Pressure  
CRA : Central Retinal Artery 
SPCA : Short Posterior Ciliary Artery 
CRV : Central Retinal Vein 
CRVO : Central Retinal Vein Occlusion 
CI : Confidence Intervel 
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INTRODUCTION 
Epidemiology:- 
 Blindness is one of the most dreaded complication of diabetes, but 
also preventable. Current statistics suggests that total no of diabetics are 
expected to rise to about 300 million cases by the year 2025. The 
development of diabetes leads to increased propensity for developing 
irreversible macrovascular and microvascular complications.  
 Diabetic retinopathy rarely develops within 5 years of the onset of 
diabetes or before puberty, but about 5% of type 2 diabetes patients 
present with diabetic retinopathy at the time of diagnosis. Diabetic 
retinopathy, a microangiopathy affecting the small blood vessels due to 
hyperglycemia, damage is caused by both microvascular leakage and 
microvascular occlusion.  
 Visual loss in diabetic retinopathy is mainly due to 
neovascularisation in type 1 diabetes and maculopathy in type 2 diabetes.  
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Diabetic maculopathy:- 
        Diabetic maculopathy (either ischemia or oedema) is more 
commonly seen in type 2, compared to type 1 diabetes. The two types of 
maculopathy are often comorbid. All individuals with diabetic 
retinopathy are at risk of maculopathy, including  ischemic maculopathy. 
Approximately 14% of diabetics have maculopathy, most commonly 
macular oedema, which typically precedes ischemia if left untreated. One 
study reported 8% of eyes affected by retinopathy had some evidence of 
ischemic maculopathy.  
Diabetic macular ischemia (DMI) remains an important cause of 
visual loss in diabetic retinopathy in large part due to the devastating and 
irreversible visual loss that it causes in a minority of cases, and it is 
characterized by the presence of Foveal Avascular Zone (FAZ)  
abnormalities.  
Importance of diabetic macular ischemia:- 
Diabetic macular ischemia is extremely difficult to detect without 
the use of fundus fluorescein angiography, and it is generally regarded as 
untreatable, unlike PDR and DME. DMI severity grading standards were 
first established in the Early Treatment Diabetic Retinopathy Study 
(ETDRS report no: 11).  
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Since then numerous studies have demonstrated the relationship 
between the DMI and the severity of the visual loss and decreased 
contrast sensitivity. Further more, most studies(2,4,10,13) have demonstrated 
the FAZ abnormalities in DR, retinal ischemia or retinal capillary 
perfusion studies in diabetic retinopathy, but only very few studies are 
there to demonstrate the relationship of diabetic macular ischemia and its 
systemic associations.  
Since the visual loss in diabetic macular ischemia is profound and 
irreversible, it is necessary to determine the associated risk factors in 
DMI and to identify the individuals at greater risk as early as possible by 
aggressively targeting the risk factors and timely intervention  to prevent 
further progression and to reduce the visual morbidity due to macular 
ischemia. 
The  purpose  of  this  study  is  to  determine  the  association  of   risk  
factors like hypertension, hyperlipidaemia, ischemic heart disease (IHD), 
nephropathy in diabetic macular ischemia, since  these  risk  factors  were 
found  to  have  common  association,  known  effects  on  DME  and  PDR,  
similar microangiopathy and ischemic pathology.  
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REVIEW OF LITERATURE 
Arthur James Ballantyne, worked on the immense problem of 
diabetic retinopathy. 
In the pre Christian era the honey urine described by susruta and 
referred to as “a melting down of the flesh and limbs to urine” by aretaeus 
of Cappadocia. 
In 1921 in toroto, Frederick grant banting and Charles Herbert best 
discovered and isolated insulin, the active principle of the beta cell of the 
islet of langerhans. 
Mylius (1937) found the AV ratio was often 2:4 instead of 2:3 in 
prodromal stage of diabetic retinopathy. 
Retinal microaneurysms originally noted by Mackenzie and 
Nettleship (1877) and attention was initially drawn by Ballantyne and 
Lowenstein, isolated sign of diabetic retinopathy. 
Retinal capillary non perfusion was 1st described by ashton in 
diabetic retina using Indian ink preparation(10). 
x Bresnick  GH,  Condit  R,  Syrjala  S,  Palta  M,  Groo  A,  Korth  K.  
Abnormalities of the foveal avascular zone in diabetic retinopathy. Arch 
Ophthalmol 1984;102:1286-93(4). The Study showed FAZ abnormalities 
 
5 
 
                                                                                                                                                                       
 
like undulations, FAZ irregularities and increased FAZ in diabetic 
retinopathy cases. 
 
x D Shukla, Chandra Mohan Kolluru, J Singh, Rajesh K John, M 
Soman, B Gandhi, R Kim, N Perumalsamy  Macular ischemia as a marker 
for nephropathy in diabetic retinopathy(1). To determine whether diabetic 
macular ischemia is associated with ischemic heart disease (IHD), 
hyperlipidaemia, hypertension (HTN) and nephropathy.  
 
x Mansour AM, Schachat A, Bodiford G, Haymond R. Foveal 
avascular zone in diabetes mellitus. Retina 1993;13:125-28(9). Retinal 
capillary nonperfusion is associated with FAZ enlargement, which is 
positively correlated with the increasing severity of the retinopathy 
particularly PDR.  
 
x Sim DA, Keane PA, Zarranz-Ventura J, Bunce CV, Fruttiger M, 
Patel PJ, Tufail A,Egan CA(6). Predictive factors for the progression of 
diabetic macular ischemia. The rate of FAZ enlargement ranges from 5%-
10% of baseline FAZ area per year in eyes with established ischemia. A 
greater macular ischemia grade was independently predictive for 
progression, and diabetic macular ischemia progression itself was 
predictive of the loss of visual function. 
Only very few studies were in the literature about Diabetic macular 
ischemia, due to difficulty in diagnosing and there is no definite treatment 
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option.  The  definite  sequence  of  evolution  of  the  DMI  are  not  well  
understood but the risk factors associated with DMI are likely those of 
diabetic retinopathy in general.  
Histological studies (9,10) showed acellular capillaries in the areas of 
capillary non perfusion in diabetic retina, patches of acellular capillaries 
coalesce to occlude the terminal arteriole, clinically it correlates with non 
perfusion of macular capillaries, diagnosed by fundus fluorescein 
angiography.  
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RISK FACTORS 
MODIFIABLE RISK FACTORS 
1. Poor control of diabetes 
Hyperglycemia is an important factor in the cascading events of 
microvascular complications due to diabetes. 
Epidemiological studies showed that strict blood glucose control 
can prevent or delay but doesnot eliminate the risk of  development or 
further progression of diabetic retinopathy (Meyer le et al 2008). 
DCCT study (15) showed that intensive glycaemic control results in 
delaying the development of retinopathy by 76%, slowed down the 
progression of diabetic retinopathy by 54%, also reduced the risk of 
albuminuria by 54%. 
The UKPDS(7) showed that intensive control of  blood glucose 
results in 25% reduction of risk of any diabetic  microvascular end point 
and 35% reduction in risk of microvascular complications for every one 
point decrease in HbA1c ( eg.,8%-7%). 
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2. Hypertension 
Diabetes and HTN mostly coexists, with a prevalence of 40-60% 
over the range of 45-75 years. It remains undiagnosed and under treated 
in the diabetic as well as in general population. Type 2 DM & HTN when 
associated, may accentuate the changes of diabetic retinopathy and also 
carries an increased risk of albuminuria and renal disease.  
Inceased blood pressure has an effect on blood flow, resulted in the 
development and progression of retinopathy by damaging the retinal 
endothelial cells(6). Diabetic and hypertensive patients showed decrease in 
macular perfusion, which can be explained by progressive capillary 
closure with decreased perfusion and increased resistance(24).  
United kingdom prospective diabetes study (UKPDS)(8) was  a  
multicentred,  randomized trial study showed that tight control of blood 
pressure less than 140/80 mm Hg slowed down the progression of 
retinopathy by 34% and also reduced the risk of microvascular and 
macrovascular complications. The UKPDS showed that the incidence of 
the retinopathy was associated with systolic blood pressure, for each 
10mm Hg decrease in mean systolic blood pressure, a 13% reduction was 
found for microvascular complications.  
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In WESDR study(11), a 10mm Hg rise in diastolic blood pressure 
was found to be associated with a 330% increased 4-year risk of 
developing macular oedema in those with type 1 diabetes and a 210% 
increased risk in those with type 2 diabetes. 
 Nørgaard et al(24) found that arterial hypertension per se is not 
associated with increased retinal changes, but it may worsen these 
changes in patients with clinically apparent nephropathy. 
3.  Proteinuria and nephropathy 
 
Nephropathy leads to rheologic, lipid and platelet abnormalities 
results in accentuation of diabetic retinopathy changes. There are reports 
that patients with renal failure having maculopathy, that improves after 
dialysis or renal transplantation.  
The gross proteinuria at baseline has been reported to be associated 
with 95% increased risk of developing  in the WESDR study (Moss et al 
1988).  The  risk  of  PDR  was  4  times  higher  in  patients  with  persistent  
microalbuminuria of 4 years. 
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4. Elevated Serum lipids 
The early treatment diabetic retinopathy study (ETDRS) showed a 
positive correlation between serum lipids and hard exudates in the macula 
and decreased visual acuity in type 2 DM patients.  
Also WESDR study reported that increased serum cholesterol 
results in increased incidence of retinal hard exudates formation, also 
increases the risk of atherosclerosis and IHD (chew EY et al.1996)(14), 
Klein BEK et al 1991-1998)(11).   
Gupta et al reported that using lipid lowering agents like statins 
along with macular photocoagulation resulted in decrease in severity of 
macular oedema and hard exudates. 
5. Anaemia 
ETDRS reported that anaemia is an independent risk factor for 
high risk PDR, 5 times increase in severe DR in low Hb. Few studies 
reported that Anaemia has been associated with progression of diabetic 
retinopathy (Davis et al 1998)  (Berman DH et al 1998). 
6. Pregnancy 
During pregnancy there are high levels of oestrogen which 
accelerates the changes of diabetic retinopathy. The risk of progression of 
DR  is  related  to  the  severity  of  DR  in  the  first  trimester,adequacy  of  
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treatment, duration of diabetes, metabolic control before pregnancy and 
the presence of coexisting HTN. DME if it develops in late pregnancy, no 
need to treat because it usually resolves after pregnancy.  
7. Smoking 
Results in hypoxia, carbon monoxide and platelet aggregation, 
associated with MI, peripheral vascular disorders. No association with 
DR incidence, but there is little evidence in the progression of retinopathy 
as described by (Muhlhauser l et al 1996)(38)., (Karamanas B et al 2005). 
8. Alcohol   
Results in decreased platelet adhesiveness, decreased fibrinogen 
and increased HDL levels. Doesn’t increase risk, may have beneficial 
effect in type 1 DM patients. 
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NON- MODIFIABLE RISK FACTORS 
1. Duration of diabetes 
Most consistent relationship observed in persons with diabetes is 
the increase in the frequency and severity of diabetic retinopathy, roughly 
50% of patients develop diabetic retinopathy after 10 years, 70% after 20 
years and 90% after 30 years of onset of the disease. According to the 
estimates of caird et al the risk of blindness for a given duration of 
diabetes increases with the age of the patient at the time of diagnosis. 
2. Sex 
Incidence is more in females than males (4:3), no significant 
differences in prevalence or progression. 
3. Genetic Factors 
Transmitted as a recessive trait, without sex linkage. 
Type 1 DM:- Majority have HLA-DR3/DR4 association, has no 
effect on risk of PDR,3-6% siblings; 8% of off springs of affected father 
are affected 
Type 2 DM:- Strong genetic predisposition, no HLA 
association,40% of siblings and 30% of off springs are affected.  
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PATHOGENESIS OF DIABETIC RETINOPATHY 
Chronic hyperglycemia is the basic cause for diabetic retinopathy.  
x When blood sugar increases it is converted to sorbitol by aldose 
 reductase and further oxidized to fructose by sorbitol 
 dehydrogenase.  
 
x The  2nd reaction is slow, leads to intracellular sorbitol 
 accumulation, there is oxidative stress due to free radical 
 generation, accumulation of advanced glycation end products and 
 excessive activation of several protein kinase c isoforms.  
x Disruption of ion channel function is an important early feature.  
Early microvascular changes before onset of diabetic retinopathy incudes 
x Thickening of basement membrane:- due to non enzymatic 
 glycation of proteins, metabolites of sorbitol pathway, altered 
 basement membrane collagen. This together with endothelial cell 
 damage, changes in RBC’s, stickiness of platelets leads to 
 microvascular occlusion. 
 
x Loss of pericytes:- selective presence of sorbitol pathway in 
 pericytes responsible for early structural and functional loss. 
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The variety of fundus changes that occur in diabetic retinopathy is 
due to multiplicity  pathologic abnormalities that may exist at all levels of 
the retinal vascular bed. 
Retinal vascular changes in diabetic retinopathy at  
x Capillary level present as – Microaneurysm, dilatation, abnormal  
 Permeability and occlusion 
x Arteriole level present as – narrowing of origin of terminal 
 arterioles, Occlusion or sheathing 
x Venular level present as – dilatation, beading, reduplication, 
 looping, Kinking, branch/central vein occlusion 
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Vascular and haematological changes seen in diabetes mellitus 
 
 
 
 
  
 
 
 
                   Retinal ischemia 
                    
                      Release of VEGF 
                 
                     Arteriovenous shunts (IRMA) 
            Neovascularisation of optic disc, retina 
                          and anterior segment       
 
Rheological changes 
RBC deformation and 
Rouleaux formation leads 
to 
Increased stickiness of 
platelets 
Increased plasma viscosity 
Thickening of capillary 
basement 
Membrane leads to 
Endothelial cell damage 
  
loss of capillary  
pericytes 
MICROVASCULAR OCCLUSION 
Microaneurysms 
Capillary leakage 
Haemorrhage 
Retinal oedema 
Hard exudates 
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OPHTHALMOSCOPIC FEATURES OF DIABETIC 
RETINOPATHY INCLUDES 
Microaneurysms are seen in the macular area, the earliest detectable 
lesion and elsewhere in relation to area of capillary non perfusion. These 
are formed due to focal dilation of capillary wall following loss of 
pericytes. 
Retinal haemorrhages both deep (dot and blot haemorrhages) and 
superficial haemorrhages (flame shaped) occur from capillary leakage. 
Oedema characterized by retinal thickening is caused by capillary 
leakage. 
Hard exudates yellowish white, waxy looking patches are arranged in 
clumps or in circinate pattern, most commonly seen in the macular area. 
Composed of lipoprotein and lipid filled macrophages. 
Cotton wool spots are small whitish fluffy superficial lesions, represent 
areas of nerve fibre infarcts. If cotton wool spots more than 8 there is 
high risk of developing PDR.  
Venous abnormalities include beading, looping and dilatation, 
Intraretinal microvascular abnormalities (IRMA), seen as fine irregular 
red lines connecting arterioles with venules, represent arteriolar-venular 
shunts. 
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Dark – blot haemorrhages representing haemorrhagic retinal infarcts. 
Neovascularisation characterized by proliferation of new vessels from 
the capillaries as NVD or NVE 
Fibrovascular formation due condensation of connective tissue around 
the new vessels. 
Vitreous haemorrhage and vitreous detachment at later stages 
Diabetic retinopathy classified as follows:- 
1. Non proliferative diabetic retinopathy (NPDR) 
2. Proliferative diabetic retinopathy (PDR) 
3. Diabetic maculopathy 
4. Advanced diabetic eye disease. 
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ABBREVIATED ETDRS CLASSIFICATION OF DIABETIC RETINOPATHY 
Stage of diabetic 
retinopathy 
Description 
Non proliferative diabetic retinopathy (NPDR) 
        Very mild Microaneurysms only 
 
          Mild NPDR 
Any or all of microaneurysm or intraretinal 
haemorrhage Hard/soft exudates may or maynot 
be present. No IRMA or venous beading 
 
Moderate NPDR 
Severe retinal haemorrhages in 1-3 quadrants or 
mild IRMA  
Significant venous beading in no more than 1 
quadrant 
Cotton wool spots commonly present 
 
Severe NPDR 
 
4-2-1 rule; one or more of severe haemorrhages 
in all 4 quadrants 
Significant venous beading in 2 or more 
quadrants 
Moderate IRMA in 1 or more quadrants 
Very severe NPDR Two or more of the criteria of the severe 
Proliferative diabetic retinopathy (PDR) 
Mild-Moderate 
PDR 
New vessels on the disc(NVD) or new vessels else 
where (NVE), but extent insignificant to meet the 
high-risk criteria.  
 
High-Risk PDR 
New vessels on the disc (NVD) (about 1/3 disc area) 
  
Any NVD with vitreous or preretinal haemorrhage 
 
NVE greater than ½ disc area with vitreous or 
preretinal haemorrhage 
Advanced 
diabetic Eye 
disease 
Preretinal haemorrhage, intragel haemorrhage, 
tractional RD, tractional retinoschisis,rubeosis iridis 
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DIABETIC MACULOPATHY 
Diabetic maculopathy (foveal oedema, exudates or ischemia) is the 
most common cause of visual impairment in diabetic patients, particularly 
type 2. The pathologic changes in diabetic maculopathy divided on an 
anatomic basis into two broad categories:-         
1. Intraretinal 
2. Preretinal and vitreo retinal 
Intra retinal changes include macular oedema which results from 
increased vascular permeability and macular ischemia caused by retinal 
vascular occlusion. 
Preretinal and vitreo retinal changes include thickening of the 
posterior vitreous surface and resultant new pre retinal membrane 
formation which from the proliferation of fibrous, glial and fibrovascular 
tissues and tractional detachment of the macula. 
CLINICALLY SIGNIFICANT MACULAR EDEMA (CSME) 
Diagnostic criteria includes 
x Thickening of the retina at or within 500 micron mt of the centre of 
 the fovea 
x Hard exudates at or within 500 micron mt of the centre of the fovea 
x Zone  of  retinal  thickening  of  1  disc  diameter,  part  of  which  is  
 within one disc diameter of the foveal centre. 
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CLINICO ANGIOGRAPHIC CLASSIFICATION OF DIABETIC 
MACULAR OEDEMA 
x Focal exudative maculopathy 
Characterized by microaneurysms, haemorrhages, hard exudates 
usually     arranged in a circinate pattern. FFA reveals focal leakage with 
adequate macular perfusion. 
x Diffuse exudative maculopathy 
Characterized by diffuse retinal oedema and thickening throughout 
the posterior pole. FFA reveals diffuse leakage at the posterior pole. 
x Ischemic maculopathy 
It occurs due to microvascular occlusion. The presence of ischemia 
may be inferred if ophthalmoscopy shows cotton wool spots in the 
macula or white thread like arterioles supplying the macula but FFA is 
the most accurate method of evaluating the blood supply. 
x Mixed maculopathy 
Combined features of ischemic and exudative maculopathy are 
present. 
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DIABETIC MACULAR ISCHEMIA 
The key symptom of ischemic maculopathy is blurred vision. 
Usually there are no visual symptoms until extensive capillary damage 
occurs in the macula. The only way of diagnosing ischemic maculopathy 
is by fundus fluorescein angiography. 
Severity of macular ischemia graded according to the following features 
       1.Focal capillary drop out 
       2.Enlargement of foveal avascular zone 
       3.occlusion of arterioles. 
Mild macular ischemia 
1. Focal capillary drop out 
2. Ophthalmoscopically: macula may appear normal 
3. FFA shows: small areas of capillary non perfusion surrounded by 
 dilated capillaries 
4. Degree of capillary occlusion consistent with normal visual acuity. 
Moderate macular ischemia 
1. Ophthalmoscopically: macula may appear normal 
2. FFA shows: enlargement of foveal avascular zone and irregularity 
 of its margins 
 
22 
 
                                                                                                                                                                       
 
3. Visual acuity remains unaffected by as much as five fold increase 
 in the area of the zone. 
Severe macular ischemia 
1. Ophthalmoscopically:  Acute stage, retinal oedema and cotton 
 wool spot may be seen but in late stages small white, thread like 
 arteriole twigs may be only evidence of ischemia. 
2. FFA demonstrates the extent of non perfusion  
3. Visual acuity grossly affected in this stage and patient gives h/o 
 sudden visual loss and central scotoma.  
The diagnosis of macular ischemia is of prognostic importance 
because the visual loss with ischemia is irreversible.  
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FUNDUS FLUORESCEIN ANGIOGRAPHY 
Chao and flocks provided the earliest description of fluorescein 
angiography in 1958 and it was introduced into clinical use in 1961 by 
Novotny & Alvis. 
Principles 
          Fluorescene is the property of certain molecule stimulated by a 
light of a shorter wave length will be excited to a higher energy level and 
emit light of a longer wave length. 
 Fluorescein (sodium fluorescein) is an orange water soluble dye, 
hydrocarbon, when injected intravenously readily diffuses through most 
of the body fluids and choriocapillaries, doesnot diffuse through retinal 
vascular endothelium and retinal pigment epithelium, eliminated by liver 
and kidneys. It is excreted in the urine over 24-48 hours. 
Fluorescein binding  
70-85% of fluorescein molecules bind to plasma albumin. The dye 
molecule also binds to blood cells, predominantly deposited on the 
surface of the erythrocytes. 
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Outer Blood-retinal barrier 
Fluorescein doesnot appear to penetrate to the major choroidal 
vessels. The choriocapillaries, however contains multiple fenestrations 
and pores through which flurorescein passes into the extra vascular space. 
Fluorescein moves readily through Bruch’s membrane but on reaching 
the retinal pigment epithelium are blocked by intercellular tight junctions 
or zonula occludentes. 
Inner Blood-retinal barrier 
 The tight junctions between retinal capillary endothelial cells, 
across which neither bound nor free fluorescein can pass. The inner 
blood-retinal barrier disruption results in leakage of both bound and free 
fluorescein into the extravascular space. 
Filters     
1. Cobalt blue excitation filter through which passes white light from 
the camera. The emerging blue light enters the eye end excites the 
fluorescein molecules in the retinal and choroidal circulation which then 
emit light of a longer wave length (yellow-green). 
2. Yellow green barrier filter allows only the emitted yellow green 
fluorescent light to pass through and it blocks the blue light if reflected 
from the eye. 
 
25 
 
                                                                                                                                                                       
 
Digital angiography   
Image capture in modern devices via charge coupled device (CCD) 
of  a  digital  camera,  with  older  cameras  using  fast  black  and  white  film,  
provides instant picture availability, easy storage and access. 
TECHNIQUE OF FFA 
Preliminaries 
 A good quality angiogram needs adequate pupillary dilation and 
clear media. The patient is asked about contraindications to FA. 
Absolute contraindication  
         Fluorescein allergy 
         H/O severe reaction to any allergen is a strong relative 
contraindication. 
Relative contraindications 
         Renal failure (lower the pregnancy fluorescein dose). 
 Allergy to iodine and seafood allergies are not contraindications to 
FA as fluorescein contains no iodine. 
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Adverse effects in FA 
1. Discolouration of skin and urine.(invariable) 
2. Extravasation of injected dye. 
3. Itching, rash. 
4. Sneezing, wheezing. 
5. Vasovagal episode or syncope (usually due to anxiety) 
6. Anaphylactic and anaphylactoid reactions. 
7. Myocardial infraction (extremely rare) 
8. Death (1:220 000). 
TECHNIQUE 
 The patient is seated comfortably in front of the fundus camera 
 and sharp focusing of the fundus done to obtain a well resolved 
 photograph, by turning the focusing dial on the camera, keeping 
 the eye piece cross hairs in sharp focus. 
 A standard venous canula should be used rather than a less secure 
 butterfly winged infusion set. The line to be checked by flushing 
 with normal saline to check patency and to exclude extravasation. 
 Sodium fluorescein usually 3ml of 25% solution is drawn into 
 syringe. 
 Fundus colour photographs are taken. 
 Red free image is captured. 
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 If indicated, a pre-injection study is performed to detect 
 autofluorescence, with both the excitation and barrier filters in 
 place. 
 Images are taken at approximately 1 second intervals, beginning 5-
 10 seconds after injection and continuing through the desired 
 phases. 
 If the pathology is monocular, control pictures of the opposite eye 
 should still be taken, usually after the transit phase has been 
 photographed in one eye. 
 If appropriate, late photographs may be taken after 10 minutes to 
 show leakage, and occasionally after 20 minutes. 
 Stereo images may be helpful to demonstrate elevation, and are 
 usually taken by manually repositioning the camera sideways or by 
 using a special device to adjust the image, such images are actually 
 pseudostereo, true stereo requiring simultaneous pictures from 
 differing angles. 
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PHASES OF ANGIOGRAM 
Arm to retinal circulation time is the mean interval between injection 
and appearance at the optic disc. Average time is 8.5 to 11 seconds. 
Angiogram consists of the following overlapping phases 
1.  Choroidal phases (pre arterial) 
2.  Arterial phase 
3.  Arteriovenous phase (capillary) 
4.  venous phase 
5.  Late (re circulation) phase. 
Choroidal phase 
  Typically occurs 9-15 secs after dye injection, characterized by 
patchy lobular filling due to leakage of free fluorescein from the 
fenestrated choriocapillaries. A cilioretinal artery if present will fill at this 
time because is derived from posterior ciliary circulation. 
Arterial phase 
  Starts about a second after the onset of choroidal fluorescence. 
Initially, only the axial segment of arterial blood fluoresces, blood plasma 
adjacent to the wall stains later.  
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Arterio-venous phase 
   Follows arterial filling, there is complete filling of the arteries and 
capillaries with early laminar flow in the veins. 
Several variation of capillaries exist. 
1. Radial peripapillary:-  capillaries  which branch perpendicularly. 
2. Perifoveal capillaries:-  originate from intraretinal arterioles. 
These capillaries form a fine lay network capillaries at the borders 
of the avascular area, form a scalloped edge. 
Venous phase 
 Retinal circulation time  is the duration of time between the first 
detection of dye in the arterial system until the detection of dye in the 
tributary venous system, about 1.2 to 2.4 seconds. Venous filling is seen 
earliest in peripapillary and macular regions. Lamellar flow in the venous 
system is the reciprocal of flow in the arterial system.  
Recirculation (late) phase 
 Demonstrates the effects of continuous recirculation, dilution and 
elimination of the dye. Approximately 30 seconds after injection, 1st high 
concentration flush of fluorescein begins to empty from choroidal and 
retinal circulation. Fluorescein is absent from retinal vasculature after 
about 10 minutes. 
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 Staining of  bruch’s  membrane choroid and sclera visible if RPE is 
lightly pigmented. Lamina cribrosa within the disc remains 
hyperfluorescent because of staining. Edge of the disc stains from the 
adjacent choriocapillaries. 
INTERPRETATION OF ANGIOGRAM 
The study of the FFA starts at the vitreous.  
 In normal angio vitreous is clear and non fluorescent. Fluorescein 
leaks into the vitreous when there is intraocular inflammation or retinal 
neovascularisation. 
 For FFA it is to divide the sensory retina into two layers inner 
vascular half and outer avascular half. Important FFA concept is that the 
normal retinal blood vessels does not leak fluorescein. 
 In FFA, RPE interpretation is important because it prevents 
fluorescein leakage from the choroid and also blocks choroidal 
fluorescence. Bruch’s membrane separates RPE from the 
choriocapillaries, which is permeable to fluorescein. Beneath the 
choriocapillaries are the larger choroidal vessels, which are impermeable 
to fluorescein. 
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Two specialized areas of the fundus needs discussion:- 
1. Macula 
2. Optic nerve head 
Macula 
 Contains only four layers ILM, outer plexiform layer, outer nuclear 
layer, layer of rods and cones. Outer plexiform layer in the macula is 
oblique, important factor in understanding the stellate appearance of 
cystoid oedema in the macula as opposed to honey comb appearance 
outside. 
The dark appearance of the fovea is due to 
1. Absence of blood vessels in FAZ  
2. Blockage of background choroidal fluorescence due to high density of 
 xanthophyll at the fovea. 
3. Pigmented epithelial cells in the macula more columnar and have 
 greater concentration of melanin and lipofuscin. 
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Optic nerve head 
Optic disc is fed by two systems:-  
1. Retinal vascular system 
2. Posterior ciliary vascular system 
Central retinal artery 
 Arises from the ophthalmic artery and it supplies the axial portion 
of the anterior portion of the optic nerve, short centrifugal branches from 
the  axial  portion  of  the  CRA  supplies  the  retrolaminar  part  of  the  optic  
nerve. No further branches of CRA until it reaches the retina. 
Short posterior ciliary arteries 
 Supplies the retrolaminar portion of the optic nerve. Also lamina 
cribrosa is supplied by centripetal branches of SPCA. 
 Because most of the disc is supplied by ciliary system, fluorescein 
appears simultaneously at the optic nerve head and choroid, before it is 
apparent in the retinal arteries. 
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Venous drainage 
Main – central retinal vein 
 Prelaminar – empties into both CRV and peripapillary choroid thus 
providing collateral drainage into CRV behind the lamina cribrosa, hence 
large dilated collaterals are frequently seen following CRVO and are 
called retinociliary veins. 
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ABNORMAL FFA 
First step to recognize areas of abnormal fluorescence:- 
1. Hypofluorescence: reduction or absence of normal fluorescence 
2. Hyperfluorescence: abnormally excess fluorescence 
Hypofluorescence 
 Any abnormally dark area of the angiographic film. 
Two possible causes are  
1. Blocked fluorescence (fluorescein is present but cannot be seen). 
2. Vascular filling defect (Fluorescein cannot be seen because it is not 
 present) 
HYPERFLUORESCENCE 
 Abnormally light area on the angio or an area showing 
fluorescence excess. 
Causes for hyperfluorescence 
1. Preinjection fluorescence 
2. Transmitted fluorescence 
3. pooling  
4. Leakage 
5. Abnormal vessels 
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FFA CHANGES IN DIABETIC RETINOPATHY 
1. Location and extent of the microaneurysms can be made out. 
2. Location of hard/soft exudates seen as blocked fluorescence. 
3. The areas of capillary non perfusion. 
4. The extent of clinically significant macular oedema(CSME). 
5. FAZ abnormalities like increased FAZ, irregularities can be made 
 out   to detect diabetic macular ischemia, difficult to diagnose 
 clinically. 
6. Presence of IRMA and its confirmation (does not leak fluorescein). 
7. Presence of NVD/NVE seen as leakage. 
8. Presence of collaterals can be made out (does not leak fluorescein). 
9. Venoous abnormalities like beading, kinking, looping can be made 
 out. 
10. Large retinal haemorrhages produces blocked fluorescence. 
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ROLE OF FFA IN DIABETIC RETINOPATHY 
1. To stage the retinopathy 
2. To determine the extent of the lesion 
3. To confirm the clinical findings 
4. To detect the lesions not made out ophthalmoscopically/slit lamp 
 biomicroscopy such as capillary dropouts / FAZ abnormalities 
5. To decide about the treatment plan 
6. To monitor the treatment 
7. For documentation 
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AIM OF THE STUDY 
 
 To determine the association of risk factors like hypertension, 
Ischemic Heart Disease, Hyperlipidaemia, Nephropathy in Type-2 
diabetic patients with Diabetic Macular Ischemia 
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MATERIALS AND METHODS 
A cross sectional study was performed on 100 diabetic patients, 
attending the outpatient department of ophthalmology, Government 
Stanley Medical College, Chennai, during a period of one year from 
November 2012 to October 2013. 
This study was done in accordance with the rules of ethical 
committee. All the subjects were explained about the nature of the 
procedure and a written informed consent was obtained.   
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INCLUSION CRITERIA  
1. Type – 2  DM patients of more than 5 years duration with diabetic 
 retinopathy/maculopathy 
2. Patients with age group of more than 40 years 
EXCLUSION CRITERIA    
1. Type – 1  Diabetes mellitus 
2. FFA not possible due to medical reasons or refusal 
3. Hazy ocular media precluding good view of the Retina 
4. Any prior photo coagulation in the macular region 
5. Concomitant ocular pathology that could potentially influence the 
 progression of retinopathy ( Glaucoma, high Myopia, Retinitis 
 pigmentosa and other causes of Optic Atrophy ) 
6. Concomitant fundus pathology that could potentially affect FAZ ( 
 Eg : Arterial / Venous   Occlusion )   
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METHODOLOGY  
Following data were collected 
1. Personal data including name, age, gender 
2. History of Diabetes mellitus, age of onset, duration, treatment 
 details. 
3. Medical history of hypertension / ischemic heart  disease/ 
 hyperlipidaemia or any other systemic illness. 
4. Detailed ophthalmic history 
5. Visual acuity by Snellen’s Chart 
6. Refraction 
7. Slit Lamp examination of anterior segment 
8. IOP by Goldman Applanation Tonometer  
9. Dilated Fundus evaluation with direct ophthalmoscope, slit lamp 
 biomicroscopy with 90D, indirect Ophthalmascopy 
10. Diabetic retinopathy graded based on an abbreviated ETDRS 
 severity scale ( Mild, Moderate severe & very Severe ) non-
 proliferative diabetic retinopathy (NPDR); early and high PDR 
11. Fundus Fluorescein Angiography was done using 3 ml of 20% 
 Sodium Fluorescein dye, following the due procedure 
12. Foveal avascular zone assessed from the frames during the 
 capillary phase 
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13. Physician Opinion obtained to rule out hypertension, renal disease, 
 ischemic heart disease and hyper lipidemia 
14. The laboratory tests included:  
x Fasting and post prandial plasma glucose levels,  
x Glycosylated haemoglobin  (HbA1c)  levels  
x Fasting plasma lipid profile 
x The blood urea and serum creatinine levels 
x Routine urine examination to r/o albuminuria 
x Electrocardiogram (ECG)  
x Echocardiogram, if needed as suggested by the cardiologist. 
Glycemic status of the patient was assessed by  
1. Fasting plasma glucose level  
2. Post prandial plasma glucose level with antidiabetic  agents  
3. HbA1C done to assess the glycemic control  
HbA1c  shows  the  average  blood  sugar  level  over  the  past  three  
months. HbA1 refers to the non-enzymatic binding of several species of 
carbohydrate to haemoglobin, whereas in HbA1c the carbohydrate is 
specifically glucose(28). When HbA1c levels are more than 6.5%, taken as 
uncontrolled glycemic status as per American diabetes association (ADA) 
2013 guidelines(29). 
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Blood pressure was recorded by sphygmomanometer in the upper arm, 
in sitting posture after 10 minutes of rest.  
The JNC criteria 7(30) followed to define systemic hypertension: 
1. Either a systolic BP of 140 mm Hg  
2. Or diastolic BP of 90 mm Hg  
3. Or the patient already on anti-hypertensive medications. 
Criteria for nephropathy was 
1. Presence of urine albuminuria and/or 
2. Blood urea >40mg/dl and/or  
3. Serum creatinine >1.5mg/dl. 
Criteria for hyperlipidaemia was  
1. Fasting plasma cholesterol level of more than 200mgs/dl 
Ischemic heart disease (IHD) was diagnosed,based on ECG changes as 
1. Elevation/depression of ST segment, 
2. Inversion of ‘T’ wave supported by echographic findings and  
3. History of previous attacks or cardiovascular surgery or 
 angioplasty  for IHD. 
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Fundus fluorescein angiography 
Study subjects were assessed for  the presence of macular Ischemia 
confirmed by  fundus fluorescein Angiography.We followed the criteria 
described by Bresnick et al(4) based on fundus fluorescein angiography to 
define macular ischemia.  
1. Mild irregularities considered as small breaks in the margin of 
FAZ seen as deep undulations.   
2. Moderate irregularities defined as abnormally dilated and 
tortuous capillaries budding into the FAZ, terminal arterioles/venules 
directly abutted FAZ margins and enlarged inter capillary spaces around 
FAZ. 
3. Severe irregularities were defined as FAZ architecture grossly 
enlarged FAZ with pruned off arterioles.  
Normal FAZ: defined as FAZ <1000 micron in the longest diameter, 
regular and round/horizontally oval in shape. 
Datas collected were entered and stored in the Microsoft excel 
sheet 2007. 
 
 
 
 
44 
 
                                                                                                                                                                       
 
DATA ANALYSIS 
Descriptive analysis of all the explanatory variables including Age, 
Sex, diabetes control and other systemic diseases was done. All the 
explanatory variables with statistically significant association in 
univariate analysis were included in the multivariate regression analysis 
to calculate adjusted odds ratios for the individual factors. The 95% CI 
and P- value for the same were computed by using multivariate logistic 
regression analysis. P- value less than 0.05 was taken as the cut off level 
to determine statistical significance. 
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OBSERVATION AND RESULTS 
A total of 100 patients, all of them who were suffering from type 2 
diabetes mellitus of more than 5 years duration with diabetic retinopathy 
were included in the final analysis. Each eye of the individuals was taken 
as a unit for further statistical analysis i.e a total of 200 eyes was included 
in the analysis. Out of total 200 eyes examined 52(26%) belonged to 50 
years or below age group. The proportion of examined eyes between 51 
to 60 years and above 60 years were 48% and 26% respectively. Females 
constituted 110 (55%) and males constituted 90 (45%) of the sample. 
(Table 1) 
Parameter Frequency Percent 
I. Age group 
<= 50 yrs 52 26.0 
51 to 60 yrs 96 48.0 
Above 60 years 52 26.0 
Total 200 100.0 
II.Gender 
Female 110 55.0 
Male 90 45.0 
Total 200 100.0 
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FIGURE 1 
AGE DISTRIBUTION 
 
Out of 100 subjects, 26 subjects (26%) belonged to less than 50 
years age group, 48 subjects (48%) belonged to 51-60 years age group 
and (26%) belonged to above 60 years age group. 
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FIGURE 2 
SEX DISTRIBUTION 
 
                                
Females constituted – 55% 
Males constituted – 45% 
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FIGURE 3 
DURATION OF DIABETES MELLITUS (N= 100) 
 
 
 
 
 
            
 
Out of the 200 eyes examined, the duration of Diabetes mellitus 
was less than 10 years in 59% of the patients, 10 to 15 years in 34% and 
more than 15 years in 7%. (Figure 3) 
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TABLE 2 
PREVALENCE OF OTHER SYSTEMIC DISEASES IN THE 
STUDY GROUP (N= 200) 
Parameter Frequency Percent 
I. Hypertension 
Present 130 65.0 
Absent 70 35.0 
II. Hyperlipidaemia 
High 118 59.0 
Normal 82 41.0 
III. Ischemic heart disease 
Present 42 21.0 
Absent 158 79.0 
IV. Nephropathy 
Present 78 39.0 
Absent 122 61.0 
 
The prevalence of other systemic diseases was analyzed.  
Hypertension was present in 65% of the study subjects. Hyperlipidaemia, 
ischemic heart disease and nephropathy were present in 59%, 21% and 
39% of study participants respectively. (Table 3) 
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FIGURE 4 
PRESENTATION OF VARIOUS STAGES OF 
DIABETIC RETINOPATHY IN % (N= 200) 
 
 
Out of 200 eyes examined about 35 eyes(17.5%) had mild NPDR 
changes, 85 (42.50%) eyes had moderate NPDR changes, 52 eyes(26%) 
showed severe NPDR changes, 9 eyes (4.5%) had very severe NPDR 
changes and 19eyes (9.5%)  had PDR changes. 
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TABLE 3 
PREVALENCE OF DIABETIC MACULAR ISCHEMIA IN  
THE STUDY GROUP (N= 200) 
 
Macular Ischemia Frequency Percent 
Present 41 20.5 
Absent 159 79.5 
Total 200 100.0 
 
The prevalence of  diabetic  macular ischemia as defined by fundus 
fluorescein angiography findings was 20.5% in the study population. 
(Table 2). 
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FIGURE 5 
LATERALITY 
 
 
 
Out of 41 eyes 12 patients (24 eyes) had bilateral diabetic macular 
ischemia and 17 patients (17 eyes) had unilateral diabetic macular 
ischemia. 
 
 
  
12
17
0
2
4
6
8
10
12
14
16
18
bilateral unilateral
nu
m
be
r o
f p
at
ie
nt
s
 
53 
 
                                                                                                                                                                       
 
FIGURE 6 
PREVALENCE OF DIFFERENT GRADES OF 
DIABETIC MACULAR ISCHEMIA   
 
    
Out of 41 eyes with diabetic macular ischemia, mild irregularities 
noted in 6 eyes, moderate irregularities noted in 22 eyes and increased 
FAZ noted in 13 eyes. 
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FIGURE 7 
PREVALENCE OF DIABETIC MACULAR ISCHEMIA WITHIN 
DIFERRENT STAGES OF DIABETIC RETINOPATHY 
    
Out of 200 eyes within different grades of retinopathy, the 
prevalence of diabetic macular ischemia noted in mild NPDR stage was 
5.71%(n=35), moderate NPDR stage was 10.50%(n=85), severe NPDR 
was 30.76%(n=52), very severe NPDR stage was 66.66%(n=9) and in 
PDR stage was 42.10%(n=19). 
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FIGURE 8 
PREVALENCE OF DIABETIC MACULAR ISCHEMIA IN 
VARIOUS STAGES OF DIABETIC RETINOPATHY 
 
 
 
Out of 41 eyes examined, it was observed that 2 eyes(4.8%) in 
mild NPDR stage, 9 eyes (2I.95%) in moderate NPDR stage, 16 
eyes(39.02%) in severe NPDR stage, 6 eyes (14.63%) in very severe 
NPDR stage and 8 eyes, (19.51%) in PDR stage showed macular 
ischemia. 
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FIGURE 9 
VISUAL ACUITY PRESENTATION IN DIFFERENT  
GRADES OF DIA MACULAR ISCHEMIA 
 
 
x Out  of  6  eyes  with  mild  macular  ischemia,  5  had  V/A  of  >  6/12  
 (83.3%) and 1 had V/A of 6/18-6/60 (16.7%). 
x Out  of  22  eyes  with  moderate  macular  ischemia,  9  had  V/A of  >  
 6/12 (40.90%) and 13 had V/A of 6/18-6/60 (59.1%) and 
x Out of  13 eyes with severe macular  ischemia,  4 had V/A of 6/18-
 6/60 (30.76%) and 9 had V/A of < 6/60 (69.23%). 
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FIGURE 10 
PRESENTATION OF VISUAL ACUITY IN DIFFERENT 
STAGES OF DIABETIC RETINOPATHY 
 
 
Analysis of visual acuity of the subjects with macular ischemia( 
n=41), we noted that  
x In  mild  NPDR  stage  out  of  2  eyes,  both  of  them  had  V/A  of  ш 
 6/12,  
x In moderate NPDR out of 9 eyes, 4 had V/A of ш 6/12(44.45%) 
 and 5 had V/A of 6/18-6/60(55.55%),  
x In severe NPDR stage out of 16 eyes 4 had V/A of ш 6/12(25%), 6 
 had V/A of 6/18-6/60(37.5%) and 6 had V/A of ч 6/60(37.5%),  
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x In  v.severe  NPDR  stage  out  of  6  eyes  1  had  V/A  of   ш 
 6/12(16.67%), 3 had V/A of 6/18-6/60(50%) and 2 had V/A of ч 
 6/60(33.33%)  and  
x In PDR stage out of  8 eyes 1 had V/A ш 6/12(12.50%), 5 had V/A 
 of 6/18-6/60(62.5%) and 2 had V/A of ч 6/60(25%). 
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TABLE 4 
ASSOCIATION BETWEEN AGE GROUP AND SEX VARIABLES  
WITH DIABETIC MACULAR ISCHEMIA 
 
Parameter 
Macular Ischemia Unadjusted 
OR 
95% CI p-
value Present Absent Lower Higher 
Age 
group 
<=50 
yrs 
11(21.2%) 41(78.8%) 1    
51 to 19(19.8%) 77 (80.2%) .920 .400 2.117 .920 
>= 61 11(21.2%) 41(78.8%) 1.000 .390 2.563 1.000 
Sex Male 73 
(81.1%) 
17(18.9%) 1    
Female 86(78.2%) 24(21.8%) 1.198 .598 2.402 .610 
 
The odds of macular ischemia were almost similar in different age 
groups. Gender had not shown any significant difference influence on  
odds of macular ischemia. (Table 4) 
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TABLE 5 
ASSOCIATION BETWEEN DURATION OF DIABETES, 
GLYCEMICCONTROL AND DIABETIC MACULAR ISCHEMIA 
Parameter 
Macular Ischemia Unadj
usted 
OR 
95% CI p-value 
(Chi square 
test) Present Absent Lower Higher 
Duration of 
diabetes 
mellitus 
More 
than 15 
years 
5 
35.7% 
9 
64.3% 
1    
Less 
than 15 
years 
36 
19.4% 
150 
80.6% 
.432 .136 1.367 .15 
HBa1c 
(gm%) 
>6.5 
32 
33.3% 
64 
66.7% 
5.3 2.4 11.8 .00 
Less 
than 6.5 
9 
8.7% 
95 
91.3% 
1    
 
Duration of diabetes mellitus had no significant impact on the 
occurrence of macular ischemia. But the odds of macular ischemia were 
5.3 times higher in patients with poorly controlled diabetes mellitus with 
Hba1c level more than 6.5gm% (OR 5.3, 95% CI 2.4 to 11.8, p value < 
0.01) 
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TABLE 6 
ASSOCIATION BETWEEN VARIOUS OTHER SYSTEMIC 
DISEASES AND DIABETIC MACULAR ISCHEMIA 
Systemic Disease 
Macular Ischemia Unadjuste
d 
OR 
95% CI p-value 
(Chi 
square 
test) 
Present Absent Lower Higher 
HTN 
Present 
29 
22.3% 
101 
77.7% 
1.388 .658 2.927 .389 
Absent 
12 
17.1% 
58 
82.9% 
1    
Hyperlipidaem
ia 
High 
21 
17.8% 
97 
82.2% 
1.490 .747 2.972 .258 
Normal 
20 
24.4% 
62 
75.6% 
1    
Ischemic heart 
Disease (IHD) Present 
6 
14.3% 
36 
85.7% 
1.7 0.7 4.4 0.3 
Absent 
35 
22.2% 
123 
77.8% 
1    
Nephropathy 
Present 
30       
38.5% 
48    
61.5% 
6.3 2.92 13.6 .00 
Absent 
11    
9.0% 
111   
91.0% 
1    
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The association between presence of other systemic diseases and 
occurrence of macular ischemia was assessed. Presence of nephropathy 
had increased the odds of macular ischemia 6.3 times when compared to 
people without nephropathy (OR 6.3, 95% CI2.9 to 13.6, p value < 0.01). 
The Presence of other systemic diseases had no significant influence on 
odds of macular ischemia. (Table 6). 
 
  
 
63 
 
                                                                                                                                                                       
 
TABLE 7 
MULTIVARIATE LOGISTIC REGRESSION ANALYSIS OF 
ASSOCIATION OF VARIOUS SCOIO DEMOGRAPHIC AND 
SYSTEMIC DISEASES WITH MACULAR ISCHEMIA (N= 200) 
 
 Adjusted ODDS 
RATIO 
 
P- Value 
95% C.I. for Odds Ratio 
Lower Upper 
I.Agegroup 
<= 50 yrs (Baseleine)     
51 to 60 yrs 1.055 .912 .409 2.718 
Above 60 years 1.491 .487 .484 4.593 
II.Gender 
Male (Baseline)     
Female .759 .500 .340 1.693 
III.Duration of diabetes mellitus 
>15 yrs(Baseline)     
<=15 yrs 1.529 .539 .394 5.930 
IV.Hba1c 
Controlled(Baseline)     
Uncontrolled 2.9 .022 1.2 7.4 
V.HTN 
Absent  (Baseline)     
present 1.291 .554 .554 3.011 
VI. Ischemic heart Disease (IHD) 
Absent (Baseline)     
present .673 .476 .226 2.001 
VII. Hyperlipidaemia 
Normal (Baseline)     
High  1.688 .201 .757 3.764 
VIII. Nephropathy 
Absent (Baseline)     
Present  4.5 .001 1.8 11.0 
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Multivariate logistic regression analysis was done to assess the 
influence of various socio demographic, diabetes related parameters and 
various systemic diseases on occurrence of macular ischemia. After 
adjusting for  the effect  of  all  other  variables in the equation the odds of  
macular ischemia were 4.5 times higher in patients with nephropathy 
(Adjusted OR 4.5,95 CI(1.8-11.0),P value .001) and the diabetic macular 
ischemia were 2.9 times higher in patients with poorly controlled diabetes 
mellitus with HbA1c level more than 6.5gm% (Adjusted OR 2.9, 95% 
CI(1.2-7.4),( p value .022) (Table 7). 
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DISCUSSION 
x In this study out of 100 subjects 26% belonged to 50 years or 
 below age group, 48% belonged to 51-60 years age group, 26% 
 belonged to above 60 years age group. (Figure 1) 
x Females  constituted  55%  and  males  constituted  45%  of  the  
 sample.(Figure 2) 
x Out of the 200 eyes examined, the duration of Diabetes mellitus 
was less than 10 years in 59% of the patients, 10 to 15 years in 
34% of patients and more than 15 years in 7% of patients. (Figure 
3) 
x Hypertension was present in 65% of the study subjects. 
Hyperlipidaemia, coronary artery disease and nephropathy were 
present in 59%, 21% and 39% of study participants respectively. 
(Table 2) 
x Out of 200 eyes examined about 35 eyes(17.5%) had mild NPDR 
 changes, 85 (42.50%) eyes had moderate NPDR changes, 52 
 eyes(26%) showed severe NPDR changes, 9 eyes (4.5%) had very 
 severe NPDR changes and 19eyes (9.5%)  had PDR 
 changes.(Figure 4)  
x Out of 200 eyes examined 41 eyes showed diabetic macular 
 ischemia accounted for 20.5% of eyes with diabetic 
 retinopathy.(Table 3) 
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x Macular ischemia was bilateral in 12 patients (24 eyes) and 
 unilateral in 17 patients (17 eyes). (Figure 5) 
Out of 41 eyes with diabetic macular ischemia (Figure 6 ) 
1. Mild irregularities noted in 6 eyes (14.63%),  
2. Moderate irregularities noted in 22 cases(53.65%) and  
3. Increased FAZ noted in 13 cases(31.70%). 
 
x Out of 200 eyes within different grades of retinopathy, the 
prevalence of diabetic macular ischemia noted in mild NPDR stage was 
5.71%(n=35), moderate NPDR stage was 10.50%(n=85), severe NPDR 
was 30.76%(n=52), very severe NPDR stage was 66.66%(n=9) and in 
PDR stage was 42.10%(n=19) (Figure 7). This showed that diabetic 
macular ischemia is more prevalent in severe stages of diabetic 
retinopathy. 
 
x Out of 41 eyes with diabetic macular ischemia, it was observed that 
2 eyes(4.8%) in mild NPDR stage (n=41), 9 eyes (2I.95%) in moderate 
NPDR stage(n=41), 16 eyes(39.02%) in severe NPDR stage(n=41), 6 
eyes (14.63%) in very severe NPDR stage(n=41) and 8 eyes(19.51%) in 
PDR stage(n=41) showed macular ischemia.(Figure 8). This showed that 
diabetic macular ischemia is more prevalent in severe stages of diabetic 
retinopathy. 
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STUDY OBSERVATIONS 
Shukla et al DMI was prevalent in 36% in eyes with mild-moderate NPDR,63% 
in eyes with early proliferative retinopathy and 70% in high-risk 
retinopathy 
Sim et al DMI was prevalent in mild-moderate NPDR stage was 46%, severe 
NPDR stage was 59.7%, and in PDR stage was 77.2%. 
Our study DMI was prevalent in mild NPDR stage was 5.71%, moderate 
NPDR stage was 10.50%,severe NPDR stage was 30.76%, v.severe 
NPDR stage was 66.66% and in PDR stage was 42.10%. 
 
 Shukla  et  al  study(1) also reported that diabetic macular ischemia 
was  more  common in severe stages of retinopathy, comparable to our 
 study. 
 Sim et al(5) reported that DMI  was  most  prevalent  in  eyes  with  
 proliferative diabetic retinopathy. 
 Our  study  also  showed  that  DMI  was  more  prevalent  in  severe  
 stages of retinopathy. 
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Visual acuity assessment of the subjects with diabetic macular 
ischemia showed (Figure 9) 
x Out  of  6  eyes  with  mild  macular  ischemia,  5  had  V/A  of  >  6/12  
 (83.3%) and 1 had V/A of 6/18-6/60 (16.7%). 
x Out  of  22  eyes  with  moderate  macular  ischemia,  9  had  V/A of  >  
 6/12 (40.90%) and 13 had V/A of 6/18-6/60 (59.1%) and 
x Out of  13 eyes with severe macular  ischemia,  4 had V/A of 6/18-
 6/60 (30.76%) and 9 had V/A of < 6/60 (69.23%). 
STUDY OBSERVATIONS 
Sim et al 8/23 eyes (34.8%) in severe; 7/45 eyes (15.6%) in moderate; 
11/103 eyes (10.7%) in mild macular ischemia showed 
decreased  visual acuity.  
Our study 9/13 eyes (69.23%)  in  severe DMI; 13/22 eyes (59.1%) in 
moderate DMI; 1/6 eyes (16.7%) in mild diabetic macular 
ischemia showed decreased visual acuity. 
x Sim  et  al(5) reported that diabetic macular ischemia is associated 
 with reduced V/A in eyes with moderate to severe ETDRS-DMI 
 grades of ischemia but preserved in milder grades. 
x Our study also showed that reduced visual acuity in moderate to 
 severe grades of diabetic macular ischemia and good visual acuity 
 maintained in milder grades of ischemia.  
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Analysis  of  V/A  of  the  subjects  with  macular  ischemia  (Figure  10)  
within different stages of diabetic retinopathy we noted that,  
x In  mild  NPDR  stage  out  of  2  eyes,  both  of  them  had  V/A  of  ш 
 6/12,  
x In  moderate  NPDR out  of  9  eyes,  4  had  V/A of  ш 6/12 (44.55%) 
 and 5 had V/A of 6/18-6/60 (55.55%),  
x In severe NPDR stage out of 16 eyes 4 had V/A of ш 6/12(25%), 6 
 had V/A of 6/18-6/60(37.5%) and 6 had V/A of < 6/60(37.5%).  
x In  v.severe  NPDR  stage  out  of  6  eyes  1  had  V/A  of   ш 
 6/12(16.67%), 3 had V/A of 6/18-6/60(50%) and 2 had V/A of < 
 6/60(33.3%)  and  
x In PDR stage out of 8 eyes 1 had V/A ш 6/12(12.50%), 5 had V/A 
 of 6/18-6/60(62.5%) and 2 had V/A of < 6/60 (25%). 
This showed that decreased visual acuity is observed more in 
severe grades of diabetic retinopathy with diabetic macular ischemia. 
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ANALYSIS OF ASSOCIATION OF RISK FACTORS IN 
DIABETIC MACULAR ISCHEMIA 
Age and gender 
On analysis of our study the odds of macular ischemia were almost 
similar in different age groups. Gender had not shown any significant 
difference influence on odds of macular ischemia. (Table 4) 
STUDY OBSERVATION 
Shukla et al Age group: p value 0.59; Gender: p value 0.40 
Our study Age group: p value 0.92; Gender: p value 0.61 
 
 Shukla  et  al  study(1) reported that there were no significant 
 differences in age and gender. 
 Our study also reported that there was no significant differences in 
 age and gender. 
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Duration of diabetes mellitus 
Duration of diabetes mellitus either more than 15 years or less than 
15 years had no significant impact on the occurence of macular ischemia. 
(Table 5). 
STUDY OBSERVATION 
Shukla et al P value 0.06, statistically not significant 
Our study P value 0.15, statistically not significant 
  
 Shukla et al(1) study reported that there were no significant 
 differences in duration of diabetes. 
 Our study also showed that duration of diabetes mellitus had no 
 significant impact on the occurence of macular ischemia. 
Poor glycemic control 
The odds of macular ischemia were 5.3 times higher in patients 
with poorly controlled diabetes mellitus with HbA1c level more than 
6.5gm% (OR 5.3, 95% CI 2.4 to 11.8, p value < 0.01) (Table 5) 
Shukla et al(1)  reported that there was no significant association of 
macular ischemia and poor glycemic control. 
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Nephropathy 
Our study analysis showed that in type 2 diabetic patients the 
association of macular ischemia and diabetic nephropathy was found to 
be statistically significant, about 4.5 times higher in patients with diabetic 
nephropathy. 
STUDY OBSERVATION 
Shukla et al (OR 2.62, 95%CI 1.16-5.92, P-value .011), strong correlation between 
macular ischemia and retinopathy 
Our study (OR 4.5, 95%CI 1.8-11.0, P-value .001), also indicates strong 
correlation between macular ischemia and retinopathy 
 
 Shukla et al(1)  reported that there was a strong positive correlation 
 between macular ischemia and diabetic nephropathy and reported 
 macular ischemia as a marker for nephropathy in diabetic 
 retinopathy. 
 Bresnick et al(2)  previously found the association between retinal 
 ischemia and nephropathy, 6 out of 8 diabetic patients with retinal 
 and macular ischemia had elevated serum creatinine. 
The association of diabetic macular ischemia and diabetic 
nephropathy can be explained by the similar micro angiopathic changes 
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occurring  at  the  end  arteries  of  both  the  retina  and  kidneys.  Similar  to  
changes that occurring at capillary basement membrane of the retinal 
arterioles, renal glomeruli also shows basement membrane thickening 
resulting in glomerular hyalinization resulting in ischemia. 
Hypertension/IHD/Hyperlipidaemia 
The association between diabetic macular ischemia and other 
systemic risk factors like Hypertension(OR:1.38;CI:.658-
2.927),IHD(OR:1.7;CI:0.7-4.4),hyperlipidaemia (OR: 1.49; CI:.747-2.97) 
were not found to be as  significant as diabetic nephropathy (Table 6). 
STUDY OBSERVATION 
Shukla et al  Hypertension (OR: 1.05; 95% CI: 0.48 to 2.32), IHD (OR: 1.125; 
95% CI: 0.45 - 2.82) and hyperlipidaemia (OR: 1.63; 95% CI: 0.72 
- 3.70) were not significantly associated with macular ischaemia 
Our study Hypertension(OR:1.38;CI:.658-2.927),IHD(OR:1.7;CI:0.7-4.4), 
hyperlipidaemia (OR: 1.49; CI:.747-2.97) were not found to be 
statistically  significant  
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x Shukla et al(1)   reported that Hypertension (OR: 1.05; 95% CI: 0.48 
 to 2.32), IHD (OR: 1.125; 95% CI: 0.45 - 2.82) and 
 hyperlipidaemia (OR: 1.63; 95% CI: 0.72 - 3.70) were not 
 significantly associated with macular ischaemia, comparable to our 
 study. 
 
x Mansour  et  al(9)  reported  that  there  is  no  correlation  of  
 hypertension  with FAZ irregularities. 
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MULTIVARIATE LOGISTIC REGRESSION ANALYSIS OF ASSOCIATION 
OF VARIOUS RISK FACTORS 
Comparison between multivariate logistic regression analysis of shukla et 
al and our study 
 
  Variable 
Shukla et al Our study 
 
OR CI(95%) for 
OR 
OR CI(95%) for OR 
Age  1.01 0.95-1.07 1.055 0.409-2.718 
DM duration 0.96 0.90-1.03 1.529 0.394-5.930 
Hypertension  0.94 0.39-2.26 1.291 0.554-3.011 
IHD 1.14 0.40-3.21 0.673 0.226-2.001 
Hyperlipidaemia  1.40 0.56-3.50 1.668 0.757-3.764 
Nephropathy  2.83 1.15-7.00 4.5 1.80-11.00 
Uncontrolled DM - - 2.9 1.20-7.40 
 
 The association of diabetic macular ischemia with nephropathy 
remains most significant about 4.5 times higher after adjusting all the 
variables including HTN, IHD, hyperlipidaemia, duration of diabetes and 
uncontrolled blood sugar as shown in multivariate logistic regression 
analysis (OR 4.5, 95%CI 1.8-11.0, P-value .001). This is comparable to 
shukla study as shown in the comparison table above. 
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 The association of diabetic macular ischemia were 2.9 times higher 
in patients with poorly controlled diabetes mellitus with Hba1c level 
more than 6.5gm% (Adjusted OR 2.9, 95% CI(1.2-7.4),( p value .022) 
This study showed that the severity of diabetic retinopathy was a 
major confounding variable and increased FAZ size and irregularities are 
known to increase with increasing severity of diabetic retinopathy. 
In this study we found that the association of diabetic macular 
ischemia is found to be statistically significant with nephropathy and 
uncontrolled diabetes mellitus. All those patients found to have 
nephropathy referred to nephrologist for detailed evaluation of the renal 
status and to the diabetologist for control of blood sugar. 
Also we found that visual acuity is preserved in milder grades of 
macular ischemia. Patients diagnosed to have diabetic macular ischemia 
are regularly followed up to rule out progression of the disease and to 
reduce the visual morbidity. 
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CONCLUSION 
x Patients with diabetic macular ischemia also suffer from other 
 systemic illness, the most significant associated risk factor being 
 diabetic nephropathy, followed by uncontrolled glycemic status. 
 
x The association between diabetic macular ischemia and other 
 systemic risk factors like Hypertension, IHD, hyperlipidaemia were 
 not found to be as significant as diabetic nephropathy. 
 
x Diabetic macular ischemia was more prevalent in severe grades of 
 retinopathy and visual acuity grossly affected in severe diabetic 
 macular ischemia. 
 
x Fundus Fluorescein Angiography is the diagnostic tool to assess 
 the ischemic status of the macula irrespective of the stage of 
 retinopathy and earlier diagnosis of diabetic macular ischemia 
 results in preservation of visual acuity by controlling the predictive 
 risk factors like uncontrolled diabetes mellitus and nephropathy. 
 
x This presence of association between the poor glycemic control 
 and diabetic macular ischemia suggests that HbA1c levels to be 
 maintained below < 6.5% and patients with poor glycemic control 
 referred to diabetologist for glycemic control. 
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x The presence of strong association between diabetic macular 
 ischemia and nephropathy suggests that Diabetic Macular Ischemia 
 serves as a marker of nephropathy. 
 
x The diagnosis of diabetic macular ischemia in type 2 diabetic 
 patients, irrespective to the stage or severity of retinopathy should 
 alert  the  ophthalmologist  to  see  the  renal  status  of  the  patient  to  
 rule out nephropathy. 
 
x Patients diagnosed to have diabetic macular ischemia are regularly 
 followed up to rule out progression of the disease or deterioration 
 of visual acuity. 
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–[S ë–Ë–¶«Ô ë–¤¯  & 
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–[S ë–Ë–¶¯ CuíÏ () SÉUP¹£. 
 
ì©ì° SÉœ—hœ–mkÇÂ ·½¤i Cªzu S¼ê© –«ì\êuíÏ B©¹  
·ª¶[PÇ GÏUS ·ÂUPœ–mhx. GÔÒíh¤ \•ìuP[PíÂ ìPmP¹£,  
AuÍPêÏ uS•u ·ÂUP[PíÂ ë–È¹£ ¶êUPÃUPœ–mhx. 
     
{êÔ C»¶ê©·µ uÔÐaí\¤êP uêÔ –[ìPÍQìÈÔ. G•u Pmhzv³£ 
G•u \mh ]UP³US£ Em–hê©µ {êÇ C»¶ê©·µ C−•x ·°QU  
ëPêÇÂ°ê£ GÔË£ AÉ•x ëPêsìhÔ.  
 
C•u –«ì\êuíÏ \£©•u©êPì¶ê, Cíu \ê¯•x ì©³£ B©¹ ì©ÍëPêÇÅ£  
ì–êx£ C•u B©·µ –[S ë–Ë£, ©−zx¶¯ GÔÒíh¤ ©−zx¶  
AÉUíPPíÂ –ê¯–uÍS GÔ AÒ©v ìuí¶¥µí° GÏ AÉ•xëPêÇQìÈÔ.  
{êÔ B©·µ C−•x ·°QUëPêshê³£ Cx ë–ê−•x£ GÏ AÉQìÈÔ. 
 
C•u B©·Ô - ô°£ QíhUP£ uP¶µPíÂ§£, –«ì\êuíÏ ¡i¹PíÂ§£  
©ÍË£ AËí¶ ]Qaí\ ëuêh¯–êÏ uP¶µPíÂ§£ ©−zx¶¯ ì©ÍëPêÇÅ£  
B©·µ –¤Ô–kzvU ëPêÇÂ¹£ Aíu —ª_«UP¹£ GÔ ¡¿ ©ÏxhÔ 
\£©vUQìÈÔ. 
C•u ·½¤i Cªzu S¼ê© –«ì\êuíÏ B©·µ –[S ëPêÇÂ Jœ™U ëPêÇQìÈÔ  
GÏUS ëPêkUPœ –mh AÉ¹íªPÃÔ –i {h•x ëPêÇ¶xhÔ C•u B©í¶ 
ì©ÍëPêÇÅ£ ©−zx¶ AoUS Esí©§hÔ C−œì–Ô GÔË£ EËv  
AÃUQìÈÔ.GÔ Ehµ –êvUPœ–mhì°ê Aµ°x Gv¯ –êªêu ¶¼UPzvÍS ©êÈêÏ 
ì{ê©SÉ ëuÔ–mhêì°ê EhìÏ Aíu ©−zx¶ AoUS ëu«·œì–Ô GÏ EËv 
AÃUQìÈÔ. 
 
 
B©¶êÂ«Ô íPë¤êœ–£.     –[ìPÍ–¶«Ô íPë¤êœ–£. 
S.
No
Name Age Sex Treatment INV INV INV INV INV INV INV
DM HTN CAD
OTHER
S
RE LE RE LE RE LE Macula  RE Macula  LE Bld sugar HbA1C % urea creatinin lipid pro urine alb ECG
1 kandasamy 46 M 15 yrs  -  -
PT 
2yrs, 
CKD
OHA, ATT 
completed
NAD NAD  6/24  6/24 PDR PDR FAZ-N FAZ-N 103(F) 6.8 80 2.7 186 2+ WNL
2 senthil 40 M 10 yrs 5yrs  -
lt dia 
foot,C
KD
OHA, anti HTN 
drugs 5th toe 
amputated
NAD NAD  6/60  6/60 PDR with CSME PDR with CSME
FAZ-N, macula 
leaks+
FAZ-N, 
macula leaks+
145(F) 6.1 170 6.7 198 2+ WNL
3 jaithun bee 45 F 13  yrs  -  -  - OHA NAD NAD  6/18  6/18 Sev.NPDR / CSME
Sev.NPDR / 
CSME
FAZ-N, macula 
leaks+
FAZ-N, 
macula leaks+
226(PP) 6.9 32 1.3 167 1+ WNL
4 Govindaraj 57 M 6 yrs  -  -  - OHA NAD
NAD,
divergent
 6/24  6/18 Sev.NPDR / CSME
Sev.NPDR / 
CSME
FAZ-N, macula 
leaks+
FAZ-N, 
macula leaks+
428(F) 8.2 18 1 159 trace WNL
5 Rajaram 45 M 15 yrs
rec.
diagno
 - PT 5yrs
OHA, anti HTN 
drugs, ATT 
completed
NAD NAD  6/12  6/24 PDR/maculopathy PDR FAZ-N
focal capillary 
dropout+
233(F) 6.8 32 1 225 trace WNL
6 kumar krishnan 38 M 6 yrs 5 yrs  -  -
OHA, anti 
HTN drugs 
NAD NAD  6/36  6/36
Sev.NPDR / CSME/gr 
2 HTN retinopathy
Sev.NPDR / 
CSME
FAZ-N, macula 
leaks+
FAZ-N, 
macula leaks+
149(PP) 6.5 26 0.8 189 nil WNL
7 krishna murthy 55 M 5 yrs 6 months  -  -
OHA, anti 
HTN drugs 
IMC IMC  6/18  6/60
Sev.NPDR / gr 2 HTN 
retinopathy
Sev.NPDR FAZ-N FAZ-N 152(F) 6.2 28 0.7 228 nil WNL
8 Kursheed banu 53 F 10 yrs  - 2 yrs  -
OHA, anti 
anginal drugs 
IMC IMC  6/24  6/60
Sev.NPDR / focal 
CSME
Sev.NPDR / 
CSME
FAZ-N, macula 
leaks+
FAZ-N, 
macula leaks+
136(F) 
259(PP)
6.9 42 0.1 252 nil changes+
9 Mohan 60 M 9 yrs  -  -  - OHA
lens 
changes
IMC  6/18  6/18 Sev.NPDR 
Sev.NPDR / 
CSME
FAZ-N
N, macula 
leaks+
276(F) 7.1 48 3.8 168 2+ ST Changes+
10 Muniammal 55 F 5 yrs  3 yrs  -  -
OHA, anti 
HTN drugs 
IMC IMC  6/18  6/60
Mod.NPDR/gr 2 HTN 
retinopathy
Mod.NPDR/
gr 2 HTN 
retinopathy
FAZ-N FAZ-N 234(F) 6.4 24 0.6 152 nil WNL
11 Kasthuri 60 F 7 yrs 2 yrs  -  -
OHA, anti 
HTN drugs 
IMC IMC  6/12  6/18 Mod.NPDR/CSME
Mod.NPDR/
CSME
FAZ-N, macula 
leaks+
FAZ-N, 
macula leaks+
116(F) 6.2 34 0.8 174 nil WNL
12 Anthony 40 F 7 yrs rec.diagno  -  -
OHA, anti 
HTN drugs 
NAD NAD  6/12  6/18 Mod.NPDR
Mild NPDR/ 
Maculopathy
FAZ-N FAZ-N 112(F) 6 27 0.8 224 nil WNL
13 Pattammal 70 F 10 yrs 3 yrs  -
OHA, anti 
HTN drugs 
PSCC PSCC  6/12  6/36 Mild NPDR
Mild 
NPDR/CSME
focal capillary 
dropout+ / macular 
leaks
FAZ-N, 
macula leaks+
166(F) 6.5 32 0.9 196 trace WNL
14 Meenakshi 57 F 10 yrs rec.diagno 2 yrs  -
OHA, anti HTN 
drugs, 
antianginal drugs
NAD NAD  6/12  6/12 Mod.NPDR Mod.NPDR FAZ-N FAZ-N 122(F) 5.9 28 0.6 223 nil changes+
15 Sathya 60 F 20 yrs  -  -  - OHA IMC IMC HM+  6/24
Sev.NPDR /? Ischaemic 
maculopathy
Sev.NPDR FAZ increased FAZ-N 142(F) 6.4 29 0.9 195 trace WNL
16 kanakambal 70 F 8 yrs 3 yrs  -  -
OHA, anti 
HTN drugs 
IMC PC IOL  6/18  6/18
Mild NPDR/ 
Maculopathy
Mod.NPDR FAZ-N FAZ-N 101(F) 6 35 1 175 nil WNL
17 Prahaladan 55 M 13 yrs 2 months  - PT 7yrs
OHA, anti 
HTN drugs, ATT 
completed
NAD NAD  6/12  6/36 PDR PDR with CSME FAZ-N FAZ-N, macula leaks+ 111(F) 6.7 30 0.5 186 nil WNL
18 lakshmi 68 F 20 yrs  -  -  - OHA PC IOL PC IOL  6/36  1/60
Sev.NPDR / 
maculopathy
Sev.NPDR / 
maculopathy
FAZ increased 
FAZ 
increased 
169(F) 7.2 41 0.8 178 trace WNL
19 Devika 52 F 5 yrs rec.diagno
 3 
month
s
 -
Insulin, anti HTN 
drugs,anti 
anginal drugs
IMC IMC  6/12  6/12 Mod.NPDR
Mild NPDR/ 
Maculopathy
FAZ-N FAZ-N 118(F) 6.2 34 0.6 168 nil changes+
20 Sakul hameed 48 M  10 yrs  6 yrs  -  -
Insulin, 
anti HTN drugs
IMC IMC  6/9  6/9 Mod.NPDR Mod.NPDR FAZ-N FAZ-N 108(F) 5.8 36 0.8 186 nil WNL
21 Revathi 52 F  10 YRS  10 YRS
 3 
month
s
 -
OHA, anti HTN 
drugs, 
antianginal drugs
Early lens 
changes+
Early lens 
changes+
 6/9  6/9
Mild NPDR/ 
Maculopathy
Mod.NPDR FAZ-N FAZ-N  119(F) 6 18 0.7 149 nil changes+
22 govindammal 55 F  5 yrs rec.diagno 1 yr  -
OHA, anti HTN 
drugs, 
antianginal drugs
Early lens 
changes+
Early lens 
changes+
 6/12  6/9 Mod.NPDR Mod.NPDR FAZ-N FAZ-N 132(F) 6.6 23 1.1 126 nil changes+
MASTER CHART 
Risk factors in yrs Ant.seg findings BCVA Fundus FFA
23 Vijaya 49 F 5 yrs 1 yr  -  -
OHA, anti 
HTN drugs 
Early lens 
changes+
Early lens 
changes+
 6/18  6/12 Sev.NPDR Sev.NPDR FAZ-N FAZ-N 138(F) 7.2 19 0.6 232 nil WNL
24 Gursheed begum 59 F 10 yrs  -  -  OHA IMC IMC  5/60  5/60 Sev.NPDR / CSME
Sev.NPDR / 
CSME
FAZ increased /       
macular leaks
FAZ increased /    
   macular leaks
236(F) 7.8 24 0.7 202 trace WNL
25 Vedanayagam 55 M 20 yrs 1 yr  -  -
OHA, anti HTN 
drugs 
IMC IMC  6/12  6/12
Mod.NPDR/ 
maculopathy
Mod.NPDR/ 
maculopathy
FAZ-N, macula 
leaks+
FAZ-N, 
macula leaks+
186(F) 6.5 22 0.5 235 trace WNL
26 Kamala 65 F 12 yrs 8 yrs 5 yrs  -
OHA, anti HTN 
drugs, 
antianginal drugs
IMC IMC  6/12  6/18 Mod.NPDR
Mild NPDR/ 
Maculopathy
FAZ-N FAZ-N 119(F) 6.3 39 0.9 196 nil changes+
27 Vimalan 46 M 10 yrs 2 yrs  -  -
OHA, anti 
HTN drugs 
NAD NAD  6/12  6/12 Sev.NPDR Sev.NPDR FAZ-N FAZ-N 138(F) 6.7 32 0.6 248 nil WNL
28 kandasamy 58 M 10 yrs  - 3 Yrs  -
OHA, antianginal 
drugs
IMC IMC  6/12  6/12 Mod.NPDR Mod.NPDR FAZ-N FAZ-N 110(F) 6.1 27 0.8 188 nil WNL
29 Vasu 46 M 8 yrs 1 yr  - CKD
OHA, anti 
HTN drugs 
NAD NAD  6/24  6/24 Sev.NPDR / CSME
Sev.NPDR / 
CSME
focal capillary 
dropout+
focal capillary 
dropout+
132(F) 6.8 83 2.7 250  1+ WNL
30 Mohan 67 M 10 yrs  -  - CKD
OHA, 
insulin 
 lens 
changes+
 lens 
changes+
 6/18  6/18
Sev.NPDR/ 
maculopathy 
Sev.NPDR / 
CSME
FAZ-N
FAZ-N, 
macula leaks+
79(F) 6.4 63 3.8 194 2+ changes+
31 Vimala devi 44 F 5 yrs  -  -  - OHA NAD NAD  6/12  6/9 Mod.NPDR Mod.NPDR FAZ-N FAZ-N 119(F) 6.1 12 0.8 189 nil WNL
32 Pankajavalli 45 F 5 yrs  -  -  -
OHA, 
insulin 
NAD NAD  6/18  6/18 Mod.NPDR/CSME
Mod.NPDR/
CSME
FAZ-N, macula 
leaks+
FAZ-N, 
macula leaks+
109(F) 6.4 26 0.9 236 nil WNL
33 lakshmi 60 F 5 yrs  -  -  - OHA 
 lens 
changes+
 lens 
changes+
 6/9  6/9 Mild NPDR
Mod.
NPDR
FAZ-N FAZ-N 98(F) 5.8 18 0.6 159 nil WNL
34 Indrani 60 F 10 yrs  -  -  - OHA PC IOL PC IOL  3/60  6/12 Sev.NPDR / CSME
Mod.NPDR/ 
maculopathy
FAZ increased/ 
macular leaks
FAZ-N, 
macula leaks+
268(F) 7.4 40 1.1 226 trace WNL
35 lakshmi Sundari 50 F 6 yrs  -  -  - OHA NAD NAD  6/9  6/6 
Mod.NPDR/ 
maculopathy
Mild NPDR/ 
Maculopathy
FAZ-N FAZ-N 86(F) 5.7 22 0.8 228 nil WNL
36 Baby 67 F 25 yrs  5 yrs  -  -
OHA, anti 
HTN drugs 
IMC IMC  6/18  6/18
Mod.NPDR/ 
maculopathy
Mod.NPDR/ 
maculopathy
FAZ-N, macula 
leaks+
FAZ-N, 
macula leaks+
95(F) 6.3 17 0.8 195 nil WNL
37 Dasarathan 48 M 5 yrs 5 yrs  -  -
OHA, anti 
HTN drugs 
NAD NAD  6/18  6/24 Mod.NPDR/CSME
Mod.NPDR/
CSME
FAZ-N, macula 
leaks+
FAZ-N, 
macula leaks+
296(F) 7.8 20 1.2 205  1+ WNL
38 Sengaiah 56 M 7 yrs 6 months  -  -
OHA, anti 
HTN drugs 
NAD NAD  6/12  6/9
Mild NPDR/ 
Maculopathy
Mild NPDR/ 
Maculopathy
FAZ-N FAZ-N 101(F) 6 17 0.5 198 nil WNL
39 Ramila 50 F 7 yrs 2 yrs 1 Yr  -
OHA, anti 
HTN 
drugs, 
antianginal drugs
NAD NAD  6/9  6/9
Mod.NPDR/ 
maculopathy
Mod.NPDR/ 
maculopathy
FAZ-N FAZ-N 284(F) 7.2 38 1.1 214 nil WNL
40 Pakkirisamy 54 M 12 yrs 6 Yrs
OHA, insulin,             
anti HTN drugs 
NAD NAD  6/18  6/18 Mod.NPDR/CSME
Mod.NPDR/
CSME
focal capillary 
dropout+ / macular 
leaks
FAZ-N, 
macula leaks+
118(F) 6.9 15 0.6 274 nil WNL
41 Sangeetha 42 F 8 yrs 5 yrs  - CKD -
OHA, anti 
HTN drugs 
NAD NAD  3/60  4/60 PDR PDR FAZ increased FAZ increased 189(F) 6.8 58 2.6 183 2+ WNL
42 Basheer 52 M 13 yrs  -  -  - OHA, insulin 
 lens 
changes+
 lens changes+  5/60  6/60 PDR/maculopathy
PDR/maculopath
y
FAZ-N, macula 
leaks+
FAZ-N, 
macula leaks+
227(F) 7.6 19 0.8 128 nil WNL
43 Raman 67 M 12 yrs 12 Yrs  -  -
OHA, anti 
HTN drugs 
PC IOL PC IOL  6/9  6/18
Mod.NPDR/ 
maculopathy
Mod.NPDR/
CSME
FAZ-N FAZ-N, macula leaks+ 132(F) 6.4 60 0.8 208 nil WNL
44 Mohana 55 F 5 yrs 3 yrs  -  -
OHA, anti 
HTN drugs 
 lens 
changes+
 lens 
changes+
 6/24  6/24 Mod.NPDR/CSME
Mod.NPDR/
CSME
FAZ-N, macula 
leaks+
FAZ-N, macula leaks+ 123(F) 6.8 17 0.5 266 nil changes+
45 Kuppammal 62 F 15 yrs 10 Yrs  -  -
OHA, anti 
HTN drugs 
IMC IMC  4/60  6/60 PDR
PDR/
maculopathy
FAZ-N
FAZ increased 
/Macular leaks
246(F) 7.9 20 0.9 145 trace WNL
46 Jeyaraj 57 F 7 yrs 7 Yrs  -  -
OHA, anti 
HTN drugs 
NAD NAD  6/12  6/9 Mod.NPDR/CSME
Mild NPDR/ 
Maculopathy
FAZ-N FAZ-N 237(F) 7.1 38 1.5 187  1+ WNL
47 Anjalai 60 F 6 yrs 1 YR  -  -
OHA, anti 
HTN drugs 
NAD NAD  6/9  6/9
Mod.NPDR/ 
maculopathy
Mod.NPDR/ 
maculopathy
FAZ-N FAZ-N 296(F) 7.5 47 0.9 231 trace WNL
48 lakshmi 50 F 6 yrs 2 yrs  -  -
OHA, anti 
HTN drugs 
NAD NAD  6/36  6/60 Mod.NPDR PDR
focal capillary 
dropout+
focal capillary 
dropout+
286(F) 8.2 36 0.8 145  1+ WNL
49 Alagu meena 55 F 6 yrs 6 yrs  -  -
OHA, anti HTN 
drugs 
IMC IMC  6/12  6/36
Mild NPDR/ 
Maculopathy
Sev.NPDR / 
CSME
Focal cap.drop outs 
/ few macular leaks
FAZ increased /  
     macular leaks
137(F) 6.5 34 0.7 187 trace WNL
50 Sankar 50 M 12 yrs  -  -  - OHA NAD NAD  6/12  6/36
Mod.NPDR/ 
maculopathy
V.Sev.NPDR/ 
maculopathy 
focal capillary 
dropout+
focal capillary 
dropout+
182(F) 6.7 52 1.3 176  1+ WNL
51 Ganesan 55 M 6 yrs  -
6 
Month
s
 -
Insulin,anti 
anginal drugs
NAD NAD  6/6  6/6 Mild NPDR Mild NPDR FAZ-N FAZ-N 140(F) 6.2 22 0.7 142 nil WNL
52 Pushpa 62 F 7 yrs 2 yrs  -  -
OHA, anti 
HTN drugs 
IMC IMC  6/36  6/36
Mild NPDR/ 
Maculopathy
Mild NPDR/ 
Maculopathy
FAZ-N FAZ-N 115(F) 6 18 0.6 185 nil WNL
53 Parameswari 63 F 15 yrs 10 Yrs  - thyroid 
OHA, anti 
HTN drugs, 
 lens 
changes+
 lens 
changes+
 6/6  6/6
Mild NPDR/ 
Maculopathy
Mild NPDR/ 
Maculopathy
FAZ-N FAZ-N 96(F) 5.9 21 0.8 167 nil WNL
54 Nagamma 70 F 8 yrs  -  -  - OHA PC IOL PC IOL  6/12  6/12
Mod.NPDR/ 
maculopathy
Mod.NPDR/ 
maculopathy
FAZ-N FAZ-N 310(F) 7.2 23 0.9 237 nil WNL
55 Indhumathy 48 F 7 yrs  -  -  - OHA NAD NAD  6/9  6/9
Mild NPDR/ 
Maculopathy
Mild NPDR/ 
Maculopathy
FAZ-N FAZ-N 121(F) 6.2 22 0.8 145 nil WNL
56 Mani 65 M 10 yrs 15 yrs  -
OHA, antianginal 
drugs
PC IOL PC IOL  6/9  6/9
Mod.NPDR/ 
maculopathy
Mod.NPDR/ 
maculopathy
FAZ-N FAZ-N 118(F) 6.3 18 0.7 208 nil WNL
57 Dhavamani 59 M 14 Yrs  -  - seizure
OHA, 
antiepileptics
PC IOL PC IOL  6/12  6/12
Mod.NPDR/ 
maculopathy
Mod.NPDR/ 
maculopathy
focal capillary 
dropout+
FAZ-N 96(F) 6.3 34 0.9 232 nil WNL
58 Arul selvi 47 F 5 yrs 6 months  -  -
OHA, anti 
HTN drugs 
NAD NAD  6/6  6/6
Mod.NPDR/ 
maculopathy
Mild NPDR/ 
Maculopathy
FAZ-N FAZ-N 225(F) 7 22 0.6 245 nil WNL
59 Chandra 55 F 6 yrs  -   -  - OHA 
 lens 
changes+
 lens 
changes+
 6/12  6/12 Sev.NPDR / CSME
Sev.NPDR / 
CSME
focal capillary 
dropout+ / macular 
leaks
focal capillary 
dropout+ / 
macular leaks
175(F) 6.8 18 0.7 231 nil WNL
60 Vahit 62 M 5 yrs  -  -
Cirrhos
is liver
OHA Early PSCC
Early 
PSCC
 6/24  6/24
Mod.NPDR/ 
maculopathy
Mod.NPDR/ 
maculopathy
FAZ-N FAZ-N 149F) 6.5 16 0.4 245 nil WNL
61 Amirtha  kani 62 F 8 yrs  -  -  - OHA NAD NAD  6/12  6/18
Mild NPDR/ 
Maculopathy
Mild NPDR/ 
Maculopathy
FAZ-N FAN-N 126(F) 5.9 21 0.6 168 nil WNL
62 Salomi 50 F 6 yrs 1 yr  -  -
OHA, anti 
HTN drugs 
NAD NAD  6/6  6/6 Mod.NPDR Mod.NPDR FAZ-N FAZ-N 168(F) 7.2 19 0.8 185 nil WNL
63 Mariyambee 63 F 5 yrs 5 yrs  -  -
OHA, anti 
HTN drugs 
 lens 
changes+
 lens 
changes+
 6/9  6/9
Mild NPDR/ 
Maculopathy
Mild NPDR/ 
Maculopathy
FAZ-N FAZ-NN 111(F) 6.2 32 0.6 196 nil WNL
64 Sunitha 48 F 8 yrs  -  -  - OHA NAD NAD  6/6                                                          6/6 Mod.NPDR Mod.NPDR FAZ-N FAZ-N 146(F) 6.1 26 0.7 239 nil WNL
65 mani 55 M 7 yrs 4 Yrs  -  -
OHA, anti 
HTN drugs 
NAD NAD  6/9  6/9
Mild NPDR/ 
Maculopathy
Mod.NPDR/ 
maculopathy
FAZ-N FAZ-N 123(F) 6.4 22 0.6 149 nil WNL
66 jaya 63 M 8 yrs 8 yrs  2 Yrs  -
OHA, anti 
HTN drugs, 
antianginal drugs
 lens 
changes+
 lens 
changes+
 6/36  6/24
v.Sev.NPDR/ 
maculopathy 
V.Sev.NPDR/ 
maculopathy 
focal capillary 
dropout+
FAZ-N, 
macula leaks+
263(F) 7.8 45 1.3 286 nil changes+
67 victoria 52 F 7 Yrs 2 yrs  -  -
OHA, anti HTN 
drugs 
NAD NAD  6/18  6/12
Mod.NPDR/ 
maculopathy
Mod.NPDR/ 
maculopathy
focal capillary 
dropout+ / macular 
leaks
FAZ-N, 
macula leaks+
235(F) 6.8 39 0.6 163 nil WNL
68 kanagaraj 58 M 11 Yrs 10 Yrs 9 yrs  -
OHA, anti 
HTN drugs, 
antianginal 
drugs
 lens 
changes+
 lens 
changes+
 6/12  6/12
Sev.NPDR/ 
maculopathy 
Sev.NPDR/ 
maculopathy 
FAZ-N FAZ-N 112(F) 6..4 21 0.5 179 trace changes+
69 Chinnakannu 72 M 21 Yrs 18 yrs 10 yrs -CKD
OHA, anti 
HTN drugs, 
antianginal drugs
PC IOL PC IOL  6/12  6/9
Mod.NPDR/ 
maculopathy
Sev.NPDR/ 
maculopathy 
FAZ-N
FAZ-N, 
macula leaks+
302(F) 8.1 73 2.3 186 1+ changes+
70 nagamma 70 F 13 Yrs 10 Yrs  -  -
OHA, anti 
HTN drugs 
PC IOL PC IOL  6/12  6/18 Mod.NPDR Sev.NPDR
focal capillary 
dropout+ / macular 
leaks
focal capillary 
dropout+
310(F) 7.4 34 0.8 286 nil WNL
71 sarbunisha 52 F 9 yrs  -  -  - OHA NAD NAD  6/9  6/9 Mild NPDR Mod.NPDR FAZ-N FAZ-N 145(F) 6.8 43 0.9 297 nil WNL
72 Mohan 50 M 6 yrs 8 yrs  -  -
OHA, anti 
HTN drugs 
NAD NAD  6/9  6/12
Mild NPDR/ 
Maculopathy
Mod.NPDR/ 
maculopathy
FAZ-N FAZ-N 218(F) 6.7 34 0.8 178 1+ WNL
73 Syed bee 65 F 15 Yrs  10 yrs 2 yrs CKD
OHA, anti 
HTN drugs, 
antianginal drugs
PC IOL PC IOL  6/12  2/60 Sev.NPDR
Sev.NPDR/ 
CSME 
FAZ-N
FAZ increased /       
macular leaks
165(F) 7.6 52 2.1 254 1+ changes+
74 Ravi chandran 56 M  8 Yrs 3 yrs  -  -
OHA, anti 
HTN drugs 
Early PSCC
Early 
PSCC
 6/12  6/18
Sev.NPDR / 
maculopathy
Sev.NPDR/ 
CSME 
FAZ-N
FAZ-N, 
macula leaks+
134(F) 6.4 51 1.6 188 trace changes+
75 Kasiammal 52 F 6 Yrs  6 Yrs  -  -
OHA, anti 
HTN drugs 
NAD NAD  6/18  6/24
Mod.NPDR/ 
maculopathy
Sev.NPDR / 
maculopathy
focal capillary 
dropout+
focal capillary 
dropout+
121(F) 6.9 34 1 225 trace WNL
76 Raman 58 M 7 yrs  - 5 yrs  -
OHA, 
antianginal drugs
NAD NAD  6/9  6/12
Mod.NPDR/ 
maculopathy
Sev.NPDR/ 
CSME 
FAZ-N
FAZ-N, 
macula leaks+
143(F) 6.2 22 0.8 264 nil changes+
77 faridabanu 60 F 9 Yrs 7 yrs  5 yrs  -
OHA, anti 
HTN drugs, 
antianginal drugs
PC IOL
PC 
IOL
 6/12  6/9
Sev.NPDR / 
maculopathy
Sev.NPDR / 
maculopathy
focal capillary 
dropout+
FAZ-N 236(F) 7.5 49 1.8 158 1+ changes+
78 kannaian 54 M 11 Yrs 12 Yrs  -  -
OHA, anti 
HTN drugs 
IMC IMC  6/24  6/24 Sev.NPDR/ CSME 
Sev.NPDR/ 
CSME 
FAZ-N, macula 
leaks+
FAZ-N, 
macula leaks+
231(F) 6.6 31 0.7 234 nil WNL
79 Indhumathy 48 F 7 Yrs  -  -  - OHA NAD NAD  6/9  6/12 PDR/maculopathy
PDR/
maculopathy
FAZ-N
focal capillary 
dropout+ /  few 
macular leaks+
129(F) 6.7 22 0.8 176 trace WNL
80 gangadhar 67 M 8 yrs  -  -  - OHA IMC IMC  6/18  6/18
Sev.NPDR / 
maculopathy
Mod.NPDR/ 
maculopathy
FAZ-N FAZ-N 145(F) 6.1 17 0.5 188 nil WNL
81 Parameswaran 53 M 11 Yrs 10 yrs 1 yr  -
OHA, anti 
HTN drugs, 
antianginal drugs
NAD NAD  6/18  6/12
Sev.NPDR / 
maculopathy
Sev.NPDR / 
maculopathy
focal capillary 
dropout+ /  few 
macular leaks+
FAZ-N 145(F) 6.3 63 1.1 197 trace changes+
82 shanthi 63 M 14 Yrs 16 Yrs  -  -
OHA, anti 
HTN drugs 
 lens 
changes+
 lens 
changes+
 6/12  6/9 Mod.NPDR
Mild NPDR/ 
Maculopathy
FAZ-N FAZ-N 122(F) 5.8 21 0.6 174 nil WNL
83 Kulasekaran 59 M 16 Yrs 16 Yrs  13 Yrs CKD
OHA, anti 
HTN drugs, 
antianginal drugs
IMC NAD  6/18  6/9
Mod.NPDR/ 
maculopathy
Mod.NPDR/ 
maculopathy
FAZ-N, macula 
leaks+
FAZ-N, macula leaks+ 142(F) 6.4 73 1.6 279 trace WNL
84 Raja 58 M 8 Yrs 10 yrs  -  CKD
OHA, anti 
HTN drugs 
PC IOL PC IOL  6/12  6/12
V.Sev.NPDR / 
maculopathy
V.Sev.NPDR / 
maculopathy
focal capillary 
dropout+ /  few 
macular leaks+
focal capillary 
dropout+ /  few 
macular leaks+
228(F) 7.3 72 1.8 243 2+ WNL
85 Mohammed ibrahim 54 M 7 Yrs 4 yrs
6 
month
s
 -
OHA, anti 
HTN drugs, 
antianginal drugs
 lens 
changes+
 lens 
changes+
 6/12  6/12
Sev.NPDR / 
maculopathy
Mod.NPDR/ 
maculopathy
focal capillary 
dropout+
FAZ-N 139(F) 6.1 21 0.6 288 NIL WNL
86 punithavathy 62 F 12 yrs  -  -  = OHA 
 lens 
changes+
 lens 
changes+
 6/12  6/18
V.Sev.NPDR / 
maculopathy
Sev.NPDR / 
maculopathy
FAZ-N, macula 
leaks+
FAZ-N, 
macula leaks+
162F) 7.5 34 1.1 187 1+ WNL
87 fathima begum 55 F 9 yrs  - 9 yrs  -
OHA, 
antianginal drugs
 lens 
changes+
 lens 
changes+
 6/6  6/9
Mild NPDR/ 
Maculopathy
Mod.NPDR FAZ-N FAZ-N 148(F) 6.4 23 0.8 196 nil WNL
88 Karuppusamy 51 M 6 yrs 6 yrs  -  -
OHA, anti 
HTN drugs 
NAD NAD  4/60  6/12
V.Sev.NPDR / 
maculopathy
Sev.NPDR / 
maculopathy
FAZ increased FAZ-N 146(F) 6.8 18 0.5 181 trace changes+
89 umarappa 48 M 6 yrs  -  -  - OHA NAD NAD  6/6  6/9 Mod.NPDR Mod.NPDR FAZ-N FAZ-N 126(F) 6.4 17 0.6 228 nil WNL
90 duraisamy 72 M 15 yrs 2 yrs  -  -
OHA, anti 
HTN drugs 
NAD NAD  6/9  6/9 Mod.NPDR
Mild NPDR/ 
Maculopathy
FAZ-N FAZ-N 136(F) 6.1 16 0.4 176 nil WNL
91 Elangovan 62 M 16 Yrs 11 yrs  -  -
OHA, anti 
HTN drugs 
IMC IMC  6/18  6/24 PDR/maculopathy
PDR/
maculopathy
focal capillary 
dropout+ /  few 
macular leaks+
FAZ 
increased 
234(F) 7.3 62 2.2 164 1+ WNL
92 suseela 52 F 8 yrs  -  -  - OHA NAD NAD  6/6  6/6
Mild NPDR/ 
Maculopathy
Mild NPDR/ 
Maculopathy
FAZ-N FAZ-N 104(F) 5.9 32 1 178 nil WNL
93 mariappan 63 M 10 Yrs 12 yrs 8 yrs  -
OHA, anti 
HTN drugs, 
antianginal 
drugs
PC IOL IMC  6/24  6/18
V.Sev.NPDR / 
maculopathy
V.Sev.NPDR / 
maculopathy
focal capillary 
dropout+ /  few 
macular leaks+
FAZ-N 145(F) 6.3 45 0.9 208 nil WNL
94 nirmala 55 F 7 yrs 7 Yrs  -  -
OHA, anti 
HTN drugs 
 lens 
changes+
 lens 
changes+
 6/9  6/9
Mod.NPDR/ 
maculopathy
Mod.NPDR/ 
maculopathy
FAZ-N
FAZ-N, macula 
leaks+
106(F) 6.4 23 0.7 176 nil WNL
95 muniyandi 49 M 6 Yrs 7 yrs  -  -
OHA, anti 
HTN drugs 
NAD NAD  6/9  6/9
Mod.NPDR/ 
maculopathy
Mod.NPDR/ 
maculopathy
FAZ-N
focal capillary 
dropout+ /  few 
macular leaks+
132(F) 6.4 32 1 176 nil WNL
96 Meera bee 52 F
7 yrs  -  -  -
OHA NAD NAD
 6/6  6/6
Mod.NPDR
Mild NPDR/ 
Maculopathy
FAZ-N FAZ-N
135(F) 6.2 20 0.5 185 nil WNL
97
Banumathy 55 F 6 yrs 6 Yrs  -  -
OHA, anti 
HTN drugs 
NAD NAD  6/18
 6/9
Mod.NPDR/CSME
Mod.NPDR/ 
maculopathy
FAZ-N, macula 
leaks+
FAZ-N
141(F) 6.6 24 0.6 236
trace
WNL
98
Mallika 55 F 8 yrs 8 yrs  -  -
OHA, anti 
HTN drugs 
NAD NAD
 6/9  6/9
Sev.NPDR / 
maculopathy
Sev.NPDR / 
maculopathy
FAZ-N FAZ-N
128(F) 6.8 26 0.8 148 nil WNL
99
kamatchi 53 F 12 yrs 12 Yrs  -  -
OHA, anti 
HTN drugs 
NAD NAD  6/12  6/12
Mod.NPDR/ 
maculopathy
Mod.NPDR/ 
maculopathy
FAZ-N
FAZ-N, 
macula leaks+ 201(F) 7.3 23 0.7 202
trace changes+
100
Karuppaiah 61 M 7 yrs 7 Yrs  -  -
OHA, anti 
HTN drugs 
NAD NAD
 6/9
 6/12
Mod.NPDR/ 
maculopathy
Sev.NPDR / 
maculopathy
FAZ-N
FAZ-N, 
macula leaks+ 123(F) 6.1 22 0.6 239
trace
WNL
